As of September 30, 2023, Alimera had cash and cash equivalents of approximately $8.3 million, compared to $18.8 million on June 30, 2023. Cash utilization during the quarter was primarily a result of the working capital investments required to support the addition of YUTIQ to Alimera. The Company expects to generate positive cash flow in the fourth quarter of 2023 and in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALIM:
- Alimera Sciences Reports Third Quarter 2023 Results
- ALIM Earnings this Week: How Will it Perform?
- Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
- Alimera Sciences appoints Jason Werner as COO
- Alimera Sciences Appoints Jason Werner as Chief Operating Officer
